Breakthrough Imtech in Belgian pharmaceutical market
Imtech will realise much of the technology in the CDPP project (Chemical Development Pilot Plant) in Geel for Janssen Pharmaceutica (part of the American pharmaceutical group Johnson & Johnson). This high-tech plant will play a pivotal role in reducing the time it takes to develop new medicines. The total investment requires 130 million euro. This assignment is unique in the sense that it involves a second party besides Imtech Belgium: the Irish Suir Engineering, acquired in December 2007 and specialising in high-tech solutions for the pharmaceutical sector. Until recently, Suir worked exclusively for the Irish pharmaceutical sector, but is now able to offer its expertise across Europe via the Imtech network of 230 European branches.
Imtech is furthermore involved as technology partner in the innovative OSD (Oral Solid Dosage) Packaging Project for pharmaceutical company Schering Plough in Heist-op-den-Berg. This project will enable Schering Plough to further improve the logistic processes for the distribution of medicines as well as raw materials and packaging components. At this location, Schering Plough completes more than 30,000 dispatch orders a year to more than 500 destinations worldwide. Imtech will furthermore be responsible for the upgrade and expansion of the technical facilities at GlaxoSmithKline (GSK) Biologicals in Saint-Amand-les-Eaux in France and the Belgian GSK branch in Wavre Nord. Finally, various smaller projects are also underway for pharmaceutical companies Purna and Pfizer, both based in the Belgian town of Puurs.
Strong position in Belgian pharmaceutical market
Imtech has continued to strengthen its position in the Belgian market for pharmaceuticals in recent years. The services portfolio consists of the multidisciplinary provision of the technical competencies of automated industrial and technical processes, electrical engineering, energy, piping and HVAC (Heating, Ventilation and Air Conditioning). Imtech is also involved in the development and implementation of technological concepts for the realisation of modular high-tech research laboratories.
Imtech in the European pharmaceutical industry
Imtech is becoming increasingly active in the pharmaceutical sector in Europe, carrying out assignments for practically the entire pharmaceutical sectors of Germany, Belgium, Ireland and the Netherlands. It has since also entered the Spanish and East European markets. An internal joint venture was launched at the beginning of 2008 so that technological competencies can be pooled and offered jointly. This approach offers extra added value, specifically through the competencies of the acquired Suir Engineering (electrical engineering and instrumentation on the highest technological level, chiefly aimed at setting up technological systems at biotechnology centres, biopharmaceutical centres and pharmaceutical production centres).
Imtech Contracting GmbH
Imtech N.V. is a European technical services provider in the fields of electrical engineering, ICT and mechanical engineering. With over 19,000 employees, Imtech achieves annual revenue of more than 3.3 billion euro. Imtech holds strong positions in the buildings, industry and infrastructure/mobility markets in the Netherlands, Belgium, Luxembourg, Germany, Eastern Europe, the UK, Ireland and Spain and in the global marine market. In total Imtech serves 14,000 customers. Imtech offers added value in the form of integrated and multidisciplinary total solutions that lead to better business processes and more efficiency for customers and the customers they, in their turn, serve. Imtech also offers solutions that contribute towards a sustainable society, for example in the areas of energy, the environment, water and mobility. Imtech shares are listed on the Euronext Stock Exchange Amsterdam, where Imtech is included in the Midcap Index. Imtech shares are also included in the Dow Jones STOXX 600 index.